# FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/folfoxiri-plus-bevacizumab-as-conversion-therapy-for-patients-with-initially/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Gianluca Tomasello,Fausto Petrelli,Michele Ghidini,Alessandro Russo,Rodolfo Passalacqua,Sandro Barni |
| Citations | 206 |
| DOI | 10.1001/jamaoncol.2017.0278 |
| Fields | Medicine |
| Open Access | true |
| OA Status | green |
| OA URL | https://www.ncbi.nlm.nih.gov/pmc/articles/5824228 |
| OpenAlex ID | https://openalex.org/W2617982897 |
| PMID | 28542671 |
| Type | article |
| Year | 2017 |

## Paper authors

- [Alessandro Russo](https://scholariq.org/researchers/alessandro-russo/)

## Paper journal

- [JAMA Oncology](https://scholariq.org/journals/jama-oncology/)

## Paper primary topic

- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

## Paper topics

- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Colorectal Cancer Surgical Treatments](https://scholariq.org/topics/colorectal-cancer-surgical-treatments/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.